There are currently 168 active clinical trials seeking participants for Heart Failure research studies. The states with the highest number of trials for Heart Failure participants are California, Florida, Texas and New York.
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
NCT06783335
Recruiting
This retrospective, non-randomized cohort study will evaluate how well the Cordella PA Sensor System works compared to standard medication treatment in people with chronic heart failure. The study will track patients for two years to see if those using the Cordella system have fewer deaths and hospitalizations related to heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Endotronix, Naperville, Illinois
Conditions: Heart Failure NYHA Class III, Heart Failure
Register for Updates
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
NCT06215586
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Cardurion Investigative Site, Birmingham, Alabama +75 locations
Conditions: Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Register for Updates
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
NCT06215911
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Cardurion Investigative Site, Birmingham, Alabama +111 locations
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Register for Updates
Pulmonary Artery Catheter in Cardiogenic Shock Trial
NCT05485376
Recruiting
The primary objective of the PACCS trial is to assess if early invasive hemodynamic assessment and ongoing management with a PAC in patients with cardiogenic shock due to acutely decompensated heart failure (AHDF-CS) is associated with lower in-hospital mortality risk compared to the current standard of care with no or delayed PAC assessment.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/14/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Cardiogenic Shock, Heart Failure
Register for Updates
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060
Recruiting
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent i... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/09/2025
Locations: Research Site, Centreville, Alabama +770 locations
Conditions: Heart Failure
Register for Updates
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574
Recruiting
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/03/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +17 locations
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction
Register for Updates
Promoting Well-being and Health in Heart Failure
NCT04829617
Recruiting
The focus of this study is to test the efficacy of a 12-week, phone-delivered Positive Psychology-Motivational Interviewing (PP-MI) intervention, with additional twice weekly PP and health behavior text messages for a total of 24 weeks (with interactive, algorithm-driven, goal-focused text messages in the final 12 weeks), compared to an attention-matched MI-based educational condition, in a randomized trial (NIH Stage II) of 280 patients with New York Heart Association class I-III Heart Failure... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Heart Failure, Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Register for Updates
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
NCT05562167
Recruiting
The goals of this project are to determine the effectiveness of acute (2 hours after a single dose) and chronic (after 6 weeks of once-a-day dosing) KNO3 treatment (10mmol) vs. placebo on quadriceps muscle power and on aerobic exercise performance (V̇O2peak) in patients with HFrEF (left ventricular ejection fraction \<45%). The investigators hypothesize that both acute and chronic dosing of 10mmol of KNO3 will improve exercise performance in HFrEF. To test this hypothesis, the investors will per... Read More
Gender:
ALL
Ages:
Between 19 years and 79 years
Trial Updated:
04/02/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Heart Failure
Register for Updates
Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart Failure
NCT06847438
Recruiting
Recent medical guidelines for the management of heart failure (HF) have established a combination of specific classes of medications as the best treatment for patients with heart failure with reduced ejection fraction (HFrEF). However, studies have shown that these medications, known together as guideline-directed medical therapy (GDMT), are not being used in clinical practice less often than they could be. Several tools to promote broader use of these treatments (including patient checklists) h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Emory Saint Joseph's Hospital, Atlanta, Georgia +3 locations
Conditions: Heart Failure
Register for Updates
Evaluating the Reach of Clinical Decision Support for Patients With Heart Failure
NCT06847906
Recruiting
To work best, clinical decision support tools (CDS) must be timed to provide support when healthcare decisions are made, which includes virtual visits (phone or video). Unfortunately, most CDS tools are either missing from virtual visits or not designed for the unique context of virtual visits (e.g., availability of physical assessments and labs, different workflows), which could generate new inequities for patients more likely to use virtual visits. The objective of this study is to test the re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: UCHealth Primary Care and Cardiology Outpatient Clinics, Aurora, Colorado
Conditions: Decision Support Systems, Clinical, Heart Failure
Register for Updates
Studies of Neuregulin/ERBB Signaling in Human Heart
NCT02820233
Recruiting
This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Maine Medical Center, Portland, Maine
Conditions: Heart Disease, Vascular Disease, Heart Failure
Register for Updates
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
NCT05677100
Recruiting
Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/28/2025
Locations: Birmingham VA Health Care System, Birmingham, Alabama +44 locations
Conditions: Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive
Register for Updates